CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017

CanniMed Therapeutics Inc. (TSX:CMED)today released its financial results for the three and nine months ended July 31, 2017. Highlights Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.

Is Smoking Cannabis the Key to a Happier, Better Life?

The studies show that consumers of marijuana tend to make more money, spend more time in the great outdoors, devote more of their time to volunteering and have a generally higher amount of happiness in their lives when compared to people who do not use cannabis. This begs the question, is marijuana the key to happiness?

Alzheimer’s Disease: Cannabis Formulation Shows Promise

Currently, India Globalization Capital (IGC) is the only publicly traded pharmaceutical cannabis stock that addresses Alzheimer’s disease, which positions the company with a first-mover advantage in phytocannabinoid-based combination therapy.

An Overview of International Markets for Canadian Cannabis Companies

As more countries begin to allow some form legalization, opportunities arise for Canadian companies to expand their business. It’s hard to ignore the fact that the boom of Canadian stocks as the country prepares for legal recreational cannabis use has been felt on a global scale.